Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Metabolic enzymes: key modulators of functionality in cancer stem-like cells.

Dong BW, Qin GM, Luo Y, Mao JS.

Oncotarget. 2017 Feb 21;8(8):14251-14267. doi: 10.18632/oncotarget.14041. Review.

2.

Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.

Chen Y, Shan Y, Lu M, DeSouza N, Guo Z, Hoffman R, Liang A, Li S.

Cancer Res. 2017 Jan 1;77(1):164-174. doi: 10.1158/0008-5472.CAN-15-2933. Epub 2016 Oct 26.

3.

Stem cell persistence in chronic myeloid leukemia.

Deininger M.

Leuk Suppl. 2012 Aug;1(Suppl 2):S46-8. doi: 10.1038/leusup.2012.24. Epub 2012 Aug 9.

4.

Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment.

Wieczorek A, Uharek L.

Biomark Insights. 2016 Feb 18;10(Suppl 3):49-54. doi: 10.4137/BMI.S22431. eCollection 2015. Review.

5.

The genome of the myxosporean Thelohanellus kitauei shows adaptations to nutrient acquisition within its fish host.

Yang Y, Xiong J, Zhou Z, Huo F, Miao W, Ran C, Liu Y, Zhang J, Feng J, Wang M, Wang M, Wang L, Yao B.

Genome Biol Evol. 2014 Nov 8;6(12):3182-98. doi: 10.1093/gbe/evu247.

6.

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia.

Lucas CM, Harris RJ, Giannoudis A, McDonald E, Clark RE.

Haematologica. 2014 Nov;99(11):1710-5. doi: 10.3324/haematol.2013.101972. Epub 2014 Sep 5.

7.

The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis.

Sharma-Walia N, Chandran K, Patel K, Veettil MV, Marginean A.

J Virol. 2014 Feb;88(4):2131-56. doi: 10.1128/JVI.02786-13. Epub 2013 Dec 11. Erratum in: J Virol. 2014 May;88(9):5206.

8.

p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice.

Velasco-Hernández T, Vicente-Dueñas C, Sánchez-García I, Martin-Zanca D.

Cell Cycle. 2013 Jan 1;12(1):122-32. doi: 10.4161/cc.23031. Epub 2012 Dec 19.

9.
10.

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.

Hansen N, Ågerstam H, Wahlestedt M, Landberg N, Askmyr M, Ehinger M, Rissler M, Lilljebjörn H, Johnels P, Ishiko J, Melo JV, Alexander WS, Bryder D, Järås M, Fioretos T.

Leukemia. 2013 Jan;27(1):130-5. doi: 10.1038/leu.2012.169. Epub 2012 Jun 22.

11.

Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes.

Boudreau LH, Maillet J, LeBlanc LM, Jean-François J, Touaibia M, Flamand N, Surette ME.

PLoS One. 2012;7(2):e31833. doi: 10.1371/journal.pone.0031833. Epub 2012 Feb 9.

12.

Recent progress in targeting cancer.

Demidenko ZN, McCubrey JA.

Aging (Albany NY). 2011 Dec;3(12):1154-62. Review.

13.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA.

Oncotarget. 2011 Mar;2(3):135-64. Review.

14.

Role of Pten in leukemia stem cells.

Peng C, Chen Y, Li D, Li S.

Oncotarget. 2010 Jun;1(2):156-60.

15.

The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?

Carter BZ, Mak DH, Cortes J, Andreeff M.

Semin Hematol. 2010 Oct;47(4):362-70. doi: 10.1053/j.seminhematol.2010.06.006. Review.

Supplemental Content

Support Center